Kuano (AI, Biotechnology) — Funding, Investors & Signals 2026

Kuano

Providing innovative quantum and AI solutions for drug discovery and design.

Founded 2020

London, United Kingdom 19 employees Seed Total: $2.80M AI, Biotechnology

Kuano is a UK-based startup that specializes in providing innovative quantum and AI solutions for drug discovery and design. Their unique approach integrates target quantum mapping and AI-led chemistry to expedite the development of superior drug candidates. By employing Quantum Mapping of targets, Kuano ensures selectivity from the outset, resulting in superior candidates in fewer design rounds. They also focus on generating better Enzyme Inhibitors by targeting Quantum Transition States, addressing the challenges of working with machine learning and quantum simulations in drug discovery. Founded in 2020, the company's recent achievement includes securing a £1.80M Seed Round investment on 12 September 2023 from notable investors including Angel CoFund, Ascension Ventures, AI Seed, o2h Ventures, Meltwind Advisory, and Mercia Ventures. Kuano's expertise in AI and biotechnology makes them an attractive prospect for collaborations with pharmaceutical and biotech companies looking for innovative approaches to drug discovery. Their network of leading academics and providers in the fields of quantum computing, AI, and machine learning further strengthens their position in the market.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	••••••	6	•••• ••••	12 Sep 2023
Seed Round	••••••	2		08 Jul 2021
Non Equity Assistance	••••••	1		01 Jan 2021
Grant	••••••	1		25 Jun 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

••••••

•••• ••••

12 Sep 2023

Seed Round

••••••

08 Jul 2021

Non Equity Assistance

••••••

01 Jan 2021

Grant

••••••

25 Jun 2020

FAQ About Kuano

Providing innovative quantum and AI solutions for drug discovery and design.

Kuano was founded in 2020.

Kuano is headquartered in London, United Kingdom.

Kuano operates in the following industries: AI, Biotechnology.

Kuano has approximately 19 employees.

Kuano has completed 4 funding rounds, raising a total of $2.80M. The latest funding stage is Seed.

Kuano offers: In-silico Drug Design with Quantum and AI, Medicinal Chemistry Expertise.

Top alternatives and competitors to Kuano include Pharmacelera, CrystalsFirst, Confluence Life Sciences, Inc., Lexicon Pharmaceuticals, Inc., Biolexis Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Kuano and Pharmacelera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Kuano

General Information

Track Kuano

Discover More

About Kuano

Services & Products

Target Customers

Funding Rounds & Investors (4)

Kuano Alternatives & Competitors

FAQ About Kuano

Don't just browse. Track.